血管生成抑制剂对晚期软组织肉瘤疗效的Meta分析

Effect of angiogenesis inhibitor on soft tissue sarcoma:a Meta-analysis

目的对血管生成抑制剂对软组织肉瘤的疗效进行Meta分析。方法计算机检索PubMed、The Cochrane Library、EMbase、CNKI数据库,按照纳入和排除标准筛选文献和提取资料,选取血管生成抑制剂治疗晚期软组织肉瘤的随机对照临床试验,采用RevMan 5.3软件进行Meta分析。检索时限均为各数据库建库起至2019年1月。结果最终纳入8篇文献,包括991例患者。Meta分析结果显示,血管生成抑制剂能有效改善半年疾病无进展率[OR = 2.44,95%CI(1.11,5.38),P = 0.03]、客观反应率[OR = 1.89,95%CI(1.15,3.10),P = 0.01]、疾病控制率[OR = 3.33,95%CI(2.46,4.53),P < 0.00 001],差异有统计学意义。半年生存率差异无统计学意义[OR = 0.94,95%CI(0.66, 1.32),P = 0.71]。结论血管生成抑制剂对晚期软组织肉瘤产生了较好疗效,能有效改善半年疾病无进展率、客观反应率、疾病控制率,在临床治疗中有使用价值。

Objective To evaluate the clinical effect of angiogenesis inhibitors on the advanced soft tissue sarcoma by Meta-analysis. Methods The database of PubMed, The Cochrane Library, EMbase and CNKI were searched by computer. After selecting the documents and extracting the data according to the inclusion and exclusion criteria, the randomized controlled clinical trials of angiogenesis inhibitors in the treatment of advanced soft tissue sarcoma was selected, and RevMan 5.3 was selected to work out the Meta-analysis. The search time was from begin of database to January 2019. Results 8 RCTs including 991 cases of patients were identified. Meta analysis showed that angiogenesis inhibitors can effectively improve the rate of progress in half a year [OR = 2.44, 95%CI (1.11, 5.38), P = 0.03], objective reaction rate [OR = 1.89, 95%CI (1.15, 3.10), P = 0.01] and disease control [OR = 3.33, 95%CI(2.46, 4.53), P < 0.00 001], there was no significant difference between angiogenesis inhibitors and control group in the half-year survival rate [OR = 0.94, 95%CI(0.66, 1.32), P = 0.71]. Conclusion Angiogenesis inhibitors are effective in the treatment of advanced soft tissue sarcoma, they can effectively improve the rate of progress in half a year, objective reaction rate and disease control and they are valuable in clinical treatment.